Answers are grounded in this paper and cite their sources.
Bladder cancer therapy faces significant challenges due to rapid drug clearance, poor urothelial penetration, and heterogeneous tumor distribution. Hydrogel-based platforms offer a versatile solution by enhancing intravesical drug retention, enabling controlled release, and supporting multifunctional interventions. These hydrogels can be engineered as mucoadhesive, thermosensitive, or field-responsive systems for intravesical delivery. Hydrogel-based immunotherapy further reshapes the tumor microenvironment, promoting local immune activation while minimizing systemic toxicity. Advanced designs incorporate tumor-responsive triggers, active transport, metabolic modulation, and extracellular matrix-targeted imaging to enable precision-guided therapy. Despite promising preclinical outcomes, translation to clinical practice requires addressing retention, safety, catheter compatibility, immunological effects, and regulatory considerations. Overall, hydrogel-based strategies represent a transformative approach for personalized, minimally invasive bladder cancer treatment, integrating chemotherapy, immunomodulation, and precision-guided interventions.
No takes yet. Share an insight, caveat, or question.
Han et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: